EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
Portfolio Pulse from Anusuya Lahiri
Nexalin Technology, Inc (NASDAQ:NXL) announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer's disease. The study showed improvements in memory and cognitive function, with significant gains in cognitive markers. The treatment was well-tolerated, indicating potential as a drug-free alternative or complement to existing treatments.

October 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology's DIFS technology showed significant improvements in cognitive function for Alzheimer's patients in a clinical trial, leading to a 4.76% increase in stock price.
The clinical trial results showing significant cognitive improvements are likely to boost investor confidence in Nexalin's technology, leading to a positive impact on the stock price. The 4.76% premarket increase reflects this sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100